Marker of human endometrial cancer, antibody and application of antibody

Abstract

The invention discloses a new human endometrial cancer tumor marker through immune mice from human endometrial cancer oncoprotein. The marker is named GAB31, and is abnormally glycosylated CD44. The marker is characterized in that CD44 contains a saccharide structure Galb1-3(Neu5Aca2-6)GlcNAcb1-4Galb1-4Glcb of epitope; in addition, a monoclonal antibody of the antigen is specifically recognized through screening, an antibody capable of specifically recognizing the antigen is obtained, and it is found through immunomagnetic bead experiments for clinical samples that the EM2D9-MB positive detection rate of a detecting method that the antibody recognizes the antigen GAB31 is obviously higher than that of a conventional cast-off cell microscopic examination method.

Description

technical field [0001] The invention belongs to the field of tumor immunology. The present invention relates to a novel endometrial cancer tumor marker GAB31 and an anti-GAB31 monoclonal antibody EM2D9. Cellular and histological levels prove that EM2D9 specifically recognizes human endometrial cancer cells and human endometrial cancer tissues. The invention also relates to a method for detecting human endometrium cancer by immunomagnetic bead method. The antigen detected by the detection method is the new human endometrial cancer marker GAB31 in the present invention, and the detection antibody is the monoclonal antibody EM2D9 against human endometrial cancer GAB31 in the present invention. Background technique [0002] Endometrial cancer is one of the most common malignant tumors of the female reproductive system, and its incidence rate ranks first among female reproductive system malignant tumors in European and American countries. Compared with European and American co...

AI Technical Summary

Problems solved by technology

Transvaginal ultrasonography cannot determine the cut-off value of endometrial lesions; patients who receive endometrial biopsy feel more or less uncomfortable, and a considerable proportion of subjects are missed diagnosis due to insufficient tissue samples; diagnostic dilatation and curettage It is an invasive operation, and it is obviously inappropriate to include it in the screening strategy, and due to the medical level, it cannot be popularized in non-developed areas; the cost of hysteroscopy is high, and its diagnostic value is limited; the characteristics of endometrial cytology are the most Approaching screening strategy, however, currently lacks uniform cytology criteria

Images